FDA approves Skyrizi (risankizumab-rzaa) for ulcerative colitis, expanding AbbVie’s portfolio across inflammatory bowel disease
AbbVie announced the FDA has approved Skyrizi (risankizumab-rzaa) for adults with moderately to severely active ulcerative colitis, making it the first IL-23 specific inhibitor approved for both moderate… read more.